Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.precisionbiosciences.com
Precision Biosciences News Releases
Get the latest updates from Precision Biosciences News Releases directly as they happen.
Follow now 40 followers
Latest posts
Last updated about 3 hours ago
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
about 4 hours ago
- PBGENE-DMD is a first-in-class in vivo gene editing approach for the...
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
7 days ago
DURHAM, N.C. --(BUSINESS WIRE)--May 8, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a...
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
8 days ago
DURHAM, N.C. --(BUSINESS WIRE)--May 7, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a...
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
14 days ago
DURHAM, N.C. --(BUSINESS WIRE)--May 1, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a...
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
16 days ago
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 29, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a...
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
30 days ago
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 15, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a...
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
about 1 month ago
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 1, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a...
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
about 2 months ago
- Announced first in vivo clinical validation for ARCUS gene editing across...
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
about 2 months ago
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 21, 2025-- Precision BioSciences, Inc. (Nasdaq: DTIL), a...
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
about 2 months ago
- PBGENE-HBV, the first and only clinical stage gene editing therapy for...
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
about 2 months ago
- Potential first-in-class gene editing approach designed for dystrophin gene correction leading...
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
about 2 months ago
- PBGENE-HBV is the first-ever investigational in vivo gene editing therapy cleared...